ASX News
Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals
HotCopper sat down with Neurizon Therapeutics MD Michael Thurn to discuss the clinical-stage biotech company's latest NUZ-001 OLE study.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| RMA | Ann: Removal from Official List | 04/01/16 | 0 | 1.6K | |||
|
|||||||
| RMA | Ann: Change of Share Registry | 05/11/15 | 0 | 1.3K | |||
|
|||||||
| RMA | Ann: Restated Annual Report for the Year Ended 30 June 2015 | 05/11/15 | 0 | 1.3K | |||
|
|||||||
| RMA | Ann: Extension of Time to Hold Annual General Meeting | 30/10/15 | 0 | 1.2K | |||
|
|||||||
| RMA | Ann: Half Yearly Report and Accounts 2014 | 28/10/15 | 0 | 1.2K | |||
|
|||||||
| RMA | Ann: Half Yearly Report and Accounts 2013 | 28/10/15 | 0 | 1.0K | |||
|
|||||||
| RMA | Ann: Half Yearly Report and Accounts 2012 | 28/10/15 | 0 | 1.0K | |||
|
|||||||
| RMA | Ann: Half Yearly Report and Accounts 2011 | 21/10/15 | 0 | 1.3K | |||
|
|||||||
See All Discussions
